CUSIP: 185860202
Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / COM NEW
-
Total 13F shares
-
786,994
-
Share change
-
-280,018
-
Total reported value
-
$4,302,641
-
Price per share
-
$5.47
-
Number of holders
-
16
-
Value change
-
-$1,529,656
-
Number of buys
-
6
-
Number of sells
-
5
Quarterly Holders Quick Answers
What is CUSIP 185860202?
CUSIP 185860202 identifies CBLI - CLEVELAND BIOLABS INC - COM NEW in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q3 2021
-
Previous quarter:
Q1 2021
Recent filing periods for CUSIP 185860202:
Institutional Holders of CLEVELAND BIOLABS INC - COM NEW (CBLI) as of Q2 2021
As of 30 Jun 2021,
CLEVELAND BIOLABS INC - COM NEW (CBLI) was held by
16 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
786,994 shares.
The largest 10 holders included
SABBY MANAGEMENT, LLC, RENAISSANCE TECHNOLOGIES LLC, VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, Cambridge Investment Research Advisors, Inc., SUSQUEHANNA INTERNATIONAL GROUP, LLP, BlackRock Inc., Sequoia Financial Advisors, LLC, NORTHERN TRUST CORP, and MORGAN STANLEY.
This page lists
16
institutional shareholders reporting positions in this security
for the Q2 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.